Skip to main content
60 DEGREES PHARMACEUTICALS, INC. logo

60 DEGREES PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · SXTP ISIN · US83006G1040 US Manufacturing
Open in API
Filings indexed 193 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country US United States of America
Listing US SXTP

About 60 DEGREES PHARMACEUTICALS, INC.

https://60degreespharma.com/

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of medicines for infectious diseases. The company's primary efforts are directed towards tropical diseases with significant unmet medical needs. Its portfolio includes a commercially available product for malaria prevention and a development program for a dengue fever treatment. The company's clinical pipeline also extends to other infectious diseases, such as babesiosis. Through collaborations with research organizations, 60 Degrees Pharmaceuticals aims to discover, develop, and distribute innovative therapies for patients worldwide.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 90% confidence The provided text is a U.S. SEC Form 8-K “Current Report” under Item 8.01 (Other Events) announcing forward-looking regulatory plans. It is a standalone regulatory disclosure without detailed financial statements or a direct earnings release, proxy materials, or a report attachment. It does not fit specialized categories like 10-K, IR, ER or M&A, so it belongs in the general Regulatory Filings category.
2026-06-03 English
CURRENT REPORT
Board/Management Information Classification · 97% confidence The document is a Form 8-K current report filed under the Securities Exchange Act, specifically Item 5.02 detailing the appointment of a new board member (Eric Francois) and changes to the company’s Board of Directors. This constitutes a board/management change announcement, fitting the Board/Management Information category.
2026-05-18 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The content describes a correction to previously reported beneficial ownership shares disclosed in a prospectus supplement. It is not a full financial report, earnings release, or management discussion, but rather a regulatory update correcting prior disclosures. The document is relatively short (4652 characters) and focuses on correcting a specific disclosure error. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-03-20 English
8-K Filing
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically discusses a Nasdaq delisting notice due to failure to maintain a minimum bid price, the company's appeal, and subsequent regaining of compliance with Nasdaq listing requirements. The document is not a full financial report, earnings release, or management discussion, but rather a regulatory announcement about the listing status of the company's stock. This fits the category of a Delisting Announcement (DLST) because it deals with the potential removal and subsequent retention of the company's stock on the Nasdaq exchange.
2026-02-12 English
CURRENT REPORT
Delisting Announcement Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The key content is the notice of delisting from Nasdaq due to failure to maintain the minimum bid price and the immediate delisting due to a recent reverse stock split. The document includes details about the delisting notice, the company's appeal, and the regulatory context. There are no financial statements or detailed financial data, nor is this an annual or quarterly report. It is a formal announcement of a delisting event, which matches the definition of a Delisting Announcement (DLST). The document length is about 5,415 characters, which is sufficient for a full announcement rather than a brief notice or a report publication announcement. Therefore, the correct classification is DLST with high confidence.
2026-01-23 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.